Posted by Michael Wonder on 18 Jan 2023
Forge Biologics receives PRIME designation from the EMA for novel gene therapy FBX-101 for the treatment of patients with Krabbe disease
17 January 2023 - FBX-101 is granted priority medicines (PRIME) designation by the EMA after review of Phase 1/2 RESKUE clinical trial safety and efficacy data.
Forge Biologics today announced that the EMA has granted priority medicines PRIME designation to FBX-101, Forge’s lead adeno-associated virus drug candidate and novel gene therapy for treating patients with Krabbe disease.
